Dyne to Present DELIVER, ACHIEVE Data at AMCP, Eyes 2027 DMD and 2028 DM1 Launch
Dyne Therapeutics will present three posters on Phase 1/2 DELIVER and ACHIEVE trial results and DM1 insurance literacy at the AMCP Conference. The company is engaging U.S. payers to contextualize functional improvement data ahead of possible z-rostudirsen launch next year and z-basivarsen launch in early 2028.
1. AMCP Conference Posters
Dyne will present three poster presentations at the AMCP Conference showcasing Phase 1/2 DELIVER trial data on z-rostudirsen for Duchenne muscular dystrophy, Phase 1/2 ACHIEVE results on z-basivarsen for myotonic dystrophy type 1, and a health insurance literacy study in DM1 patients.
2. Payer Engagement Strategy
The company is supporting a continuing education symposium titled “High-Stakes Access: Aligning Managed Care Policy with the Urgency of Treatment in Duchenne Muscular Dystrophy” on April 14 via an independent grant to engage managed care professionals on functional improvement measures from its trials.
3. Launch Preparation and Timelines
Dyne is contextualizing clinical data now to shape U.S. payer access decisions ahead of a potential z-rostudirsen DMD launch in 2027 and a z-basivarsen DM1 launch in early 2028.